BioCryst, Presidio Call Off Merger

BioCryst Pharmaceuticals (Nasdaq: BCRX  ) and privately held Presidio Pharmaceuticals today announced the termination of the companies' merger agreement, originally entered into Oct. 17. The merger was scheduled to close in the first quarter of 2013, and the all-stock transaction valued Presidio at approximately $101 million. Presidio focuses on hepatitis C treatments.

"Although the original rationale for the merger had merit, the parties determined that terminating the merger was in the best interest of both companies and their respective shareholders at this time," the companies said. Dissolution of the merger agreement has been approved by the boards of directors of each company.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 30, 2012, at 1:49 PM, rqtect wrote:

    This being called off was the best thing for BCRX

    This should get back to $4

Add your comment.

DocumentId: 2134635, ~/Articles/ArticleHandler.aspx, 4/16/2014 3:53:39 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement